Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 26,105 Shares

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 26,105 shares of the company’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $4.89, for a total transaction of $127,653.45. Following the completion of the sale, the insider directly owned 682,482 shares in the company, valued at approximately $3,337,336.98. The trade was a 3.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The shares were sold at an average price of $5.10, for a total transaction of $64,071.30.
• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The stock was sold at an average price of $5.12, for a total value of $100,459.52.
• On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total transaction of $179,877.50.
• On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $56,900.25.
• On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The stock was sold at an average price of $6.09, for a total transaction of $19,457.55.
• On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The stock was sold at an average price of $6.29, for a total transaction of $24,770.02.
• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The stock was sold at an average price of $6.04, for a total transaction of $18,790.44.
• On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The shares were sold at an average price of $5.87, for a total value of $34,451.03.
• On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total transaction of $23,005.95.
• On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The stock was sold at an average price of $5.81, for a total transaction of $76,081.95.

Clene Stock Up 2.0%

CLNN traded up $0.10 during trading hours on Friday, hitting $5.21. The stock had a trading volume of 31,933 shares, compared to its average volume of 130,336. The stock has a market cap of $56.57 million, a PE ratio of -1.53 and a beta of 0.87. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50. The company’s fifty day simple moving average is $7.23 and its 200 day simple moving average is $6.44.

Clene (NASDAQ:CLNN) last posted its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. As a group, equities analysts expect that Clene Inc. will post -5.19 EPS for the current year.

Analyst Ratings Changes

CLNN has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a research note on Friday, January 9th. Benchmark reaffirmed a “buy” rating on shares of Clene in a research note on Thursday, December 4th. UBS Group reaffirmed a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $23.00 target price on shares of Clene in a research note on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Clene currently has an average rating of “Moderate Buy” and a consensus target price of $32.60.

Hedge Funds Weigh In On Clene

Several large investors have recently made changes to their positions in the stock. Scoggin Management LP raised its position in Clene by 75.1% in the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after purchasing an additional 107,250 shares in the last quarter. Lunt Capital Management Inc. increased its stake in Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after purchasing an additional 21,217 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Clene in the second quarter valued at about $47,000. Finally, Jones Financial Companies Lllp acquired a new stake in shares of Clene during the third quarter valued at $29,000. 23.28% of the stock is currently owned by institutional investors and hedge funds.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).